- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Merz to acquire Neocutis
Merz Pharma Group has entered into an agreement with Neocutis to acquire its cosmetic, prescription and over-the-counter skincare products.
Merz Pharma Group has entered into an agreement with Neocutis to acquire its cosmetic, prescription and over-the-counter skincare products.
Neocutis, a Swiss company, manufactures products for anti-aging, pigmentation problems and sun protection. Merz’s product line includes dermal fillers such as Radiesse and Belotero, plus the neurotoxin Xeomin.
“This transaction is an important step to expand our U.S. business, as Neocutis products are an excellent addition to our own aesthetics portfolio,” Philip Burchard, Merz CEO, said in a news release.
Neocutis was founded in 2003, with the United States serving as its main market. Its products are most often used for pre- and post-treatments for aesthetic procedures.
